Department of Orthopaedic Oncology and Reconstructive Surgery, Azienda Ospedaliero-Universitaria Careggi, University of Florence, Largo Palagi 1, 50139, Florence, Italy.
Unit of Medical Statistics, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
Arch Orthop Trauma Surg. 2022 Apr;142(4):681-690. doi: 10.1007/s00402-021-03929-6. Epub 2021 May 24.
Burch-Schneider-like antiprotrusio cages (B-SlAC) still remain helpful implants to bridge severe periacetabular bone losses. The purpose of this study was to evaluate outcomes and estimate both cages' failures and complication risks in a series of B-SlAC implanted in revision of failed total hip arthroplasties (THA) or after resection of periacetabular primary or secondary bone malignancies. Risk factors enhancing the chance of dislocations and infections were checked.
We evaluated 73 patients who received a B-SlAC from January 2008 to January 2018. Group A, 40 oncological cases (22 primary tumors; 18 metastases); Group B, 33 failed THAs. We compared both Kaplan-Meier estimates of risk of failure and complication with the cumulative incidence function, taking account the competing risk of death. Cox proportional hazards model was utilized to identify possible predictors of instability and infection. Harris hip score HHS was used to record clinical outcomes.
Medium follow-up was 80 months (24-137). Average final HHS was 61 (28-92), with no differences within the two groups (p > 0.05). The probabilities of failure and complications were 57% and 26%, respectively, lower in the oncologic group than in the rTHA group (p =0 .176; risk 0.43) (p = 0.52; risk 0.74). Extended ileo-femoral approach and proximal femur replacement (p =0.02, risk ratio = 3.2; p = 0.04, rr = 2.1) were two significant independent predictors for dislocations, while belonging to group B (p = 0.04, rr = 2.6) was predictable for infections.
Burch-Schneider-like antiprotrusio cages are a classical non-biological acetabular reconstruction method that surgeons should bear in mind when facing gross periacetabular bone losses, independently of their cause. However, dislocation and infection rates are high. Whenever possible, we suggest preserving the proximal femur in revision THA, and to use a less-invasive postero-lateral approach to reduce dislocation rates in non-oncologic cases.
布奇-施耐德型抗后脱位假体(B-SlAC)仍然是一种有用的植入物,可用于桥接严重的髋臼骨缺损。本研究的目的是评估在一系列因翻修失败的全髋关节置换术(THA)或原发性或继发性髋臼骨恶性肿瘤切除后接受 B-SlAC 植入的患者中,该假体的疗效,并估计假体失败和并发症的风险。同时检查了增加脱位和感染风险的因素。
我们评估了 2008 年 1 月至 2018 年 1 月期间接受 B-SlAC 植入的 73 例患者。A 组 40 例为骨肿瘤患者(22 例为原发性肿瘤;18 例为转移瘤);B 组 33 例为翻修 THA 失败的患者。我们比较了 Kaplan-Meier 风险估计和并发症的累积发生率函数,同时考虑了死亡的竞争风险。Cox 比例风险模型用于确定不稳定和感染的可能预测因素。髋关节 Harris 评分(HHS)用于记录临床结果。
平均随访 80 个月(24-137 个月)。最终平均 HHS 为 61 分(28-92 分),两组之间无差异(p>0.05)。肿瘤组的假体失败和并发症概率分别为 57%和 26%,低于翻修 THA 组(p=0.176;风险比 0.43)(p=0.52;风险比 0.74)。延长的髂股入路和股骨近端置换(p=0.02,风险比=3.2;p=0.04,RR=2.1)是导致脱位的两个显著独立预测因素,而属于 B 组(p=0.04,RR=2.6)是感染的预测因素。
布奇-施耐德型抗后脱位假体是一种经典的非生物髋臼重建方法,当面对严重的髋臼骨缺损时,外科医生应牢记这一点,而不论其病因如何。然而,脱位和感染的发生率较高。在翻修 THA 时,我们建议尽可能保留股骨近端,并采用微创的后外侧入路,以降低非肿瘤病例的脱位率。